You are here:

atomoxetine (Strattera)

Advice

following a full submission

atomoxetine (Strattera®) is accepted for use within NHS Scotland.

Indication under review: treatment of attention-deficit/hyperactivity disorder (ADHD) in adults as part of a comprehensive treatment programme. The presence of symptoms that were pre-existing in childhood should be confirmed.

Short term studies in adults have shown that atomoxetine improves symptoms of ADHD compared to placebo. 

The economic case for atomoxetine has been demonstrated for a treatment duration of one year.

Drug Details

Drug Name: atomoxetine (Strattera)
SMC Drug ID: 909/13
Manufacturer: Lilly UK
Indication: Treatment of attention-deficit/hyperactivity disorder (ADHD) in adults as part of a comprehensive treatment programme. The presence of symptoms that were pre-existing in childhood should be confirmed.
BNF Category:
Sub Category: 4.1 Hypnotics and axiolytics
Submission Type: Full submission
Status: Accepted
Date Advice Published: 11 November 2013

Back